Dysmenorrhea is the term used to describe the pain and cramping associated with menstruation. It is estimated that dysmenorrhea is the most common gynecological condition affecting women and can occur in the absence or presence of other conditions (like endometriosis). Primary dysmenorrhea is menstrual pain that is not related to any other condition. Dysmenorrhea can start shortly after a woman’s first menstrual period and last through menopause.
Estimates indicate 50% of all women worldwide experience primary dysmenorrhea and some prevalence rates indicate that as many as 90% of all women experience dysmenorrhea at some time in their lives. In the United States, it has been estimated that 100 million work hours are lost per year due to dysmenorrhea which could translate into $2 billion in lost work productivity.
More than half of all women who experience primary dysmenorrhea indicate that their pain is moderate to severe in nature. Multiple treatments have been used throughout recent history to ameliorate dysmenorrhea including herbal supplements, aspirin, non-steroidal anti-inflammatory agents, prescription pain medications and oral contraceptives.
In keeping with our dedication to developing pharmaceutical agents to treat diseases and disorders of women, FemmePharma Global Healthcare, Inc. is pursuing research and development of novel drug compounds for primary dysmenorrhea. Using our innovative and proprietary technologies we hope to treat the overwhelming numbers of women suffering from primary dysmenorrhea.
on the links below to search for more information on Dysmenorrhea.